← All trials
NCT01744249
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2011
- Primary completion
- Jul 1, 2015
- Completion date
- Dec 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Grupo Espanol de Tumores Neuroendocrinos (GETNE)Lead sponsor
- University of ZaragozaOverall official - principal investigator
- OsakidetzaOverall official - principal investigator
- University Hospital Virgen de las NievesOverall official - principal investigator
- Hospital Clara CampalOverall official - principal investigator
- Hospital Universitario de LeónOverall official - principal investigator
- ICO Hospital Durans i ReynalsOverall official - principal investigator
- University of ValenciaOverall official - principal investigator
- University of CantabriaOverall official - principal investigator
- University of SevilleStudy director
- University of SalamancaOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- Universidad Autonoma de MadridOverall official - principal investigator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- Hospital Universitario Central de AsturiasOverall official - principal investigator
- University of BurgosOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.